Ferric Carboxymaltose Patent Expiration
Ferric Carboxymaltose is Used for treating iron deficiency anemia in patients with various underlying conditions using intravenous ferric carboxymaltose. It was first introduced by American Regent Inc
Ferric Carboxymaltose Patents
Given below is the list of patents protecting Ferric Carboxymaltose, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Injectafer | US7754702 | Methods and compositions for administration of iron | Feb 15, 2028 | Am Regent |
| Injectafer | US7612109 | Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes | Feb 05, 2027 | Am Regent |
| Injectafer | US11364260 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US11433091 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US11478502 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US8895612 | Methods and compositions for administration of iron | Jan 08, 2027 | Am Regent |
| Injectafer | US10519252 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US11123321 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US11291645 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US11590097 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
| Injectafer | US9376505 | Aqueous iron carbohydrate complexes, their production and medicaments containing them |
Oct 20, 2023
(Expired) | Am Regent |
Ferric Carboxymaltose's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ferric Carboxymaltose:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Intravenous Iron in the Management of Drug-resistant Restless Legs syndromeI | University Hospital, Montpellier | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia | AFT Pharmaceuticals, Ltd. | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Comparative Analysis of Oral Iron With Injectable Ferric Carboxymaltose for Post Partum Iron Deficiency Anaemia | ESI-PGIMSR, Basaidarapur | NA |
COMPLETED
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions | Sichuan Huiyu Pharmaceutical Co., Ltd | NA |
RECRUITING
(May 1, 2026)
| PHASE1 |